Cases
Obalon Therapeutics, Inc. (OBLN)
Securities Class Action
Overview
Overview
- Date:
- 1/23/2018
- Company Name:
- Obalon Therapeutics, Inc.
- Stock Symbol:
- OBLN
- Status:
- Closed/Complete
NEW YORK, January 23, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Obalon Therapeutics, Inc. (NYSE: OBLN). Our investigation concerns potential breach of fiduciary duty and securities claims.
On January 23, 2018, Obalon announced the termination of the underwriting agreement and cancellation of its previously announced public stock offering, after, according to the Company, a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.
Following this news, the stock price of Obalon fell $1.73 per share, or over 33%, to close at $3.46 per share on January 23, 2017.
If you purchased or otherwise acquired Obalon shares and suffered a loss, continue to hold shares, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 23, 2018, Obalon announced the termination of the underwriting agreement and cancellation of its previously announced public stock offering, after, according to the Company, a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.
Following this news, the stock price of Obalon fell $1.73 per share, or over 33%, to close at $3.46 per share on January 23, 2017.
If you purchased or otherwise acquired Obalon shares and suffered a loss, continue to hold shares, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.